TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer We evaluated the efficacy and safety of ...
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery ...
The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
In a new phase 3, double-blind study, researchers explored the efficacy and safety of combination therapy using subcutaneous (SC) belimumab and rituximab for the treatment of active systemic lupus ...
Vielight Neuro RX Gamma device and irradiation configuration used in the randomized, double-blind, sham-controlled trial. The ...
“Can the blind lead the blind? Shall they not both fall into the pit?” Luke 6:39 While “the blind leading the blind” has become an often-used idiom of incompetency and ineffectiveness, the “randomized ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results